16-2-2-2　ⓔ文献

  1. Kawabata Y, Nishida N, et al: Genome–wide association study confirming a strong effect of HLA and identifying variants in CSAD/lnc–ITGB7–1 on chromosome 12q13.13 associated with susceptibility to fulminant type 1 diabetes. Diabetes, 2019; 68: 665–675.

  2. Baden MY, Imagawa A, et al: Characteristics and clinical course of type 1 diabetes mellitus related to anti–programmed cell death–1 therapy. Diabetol Int, 2018; 10: 58–66.

  3. Okamoto M, Okamoto M, et al: Fulminant type 1 diabetes mellitus with anti–programmed cell death–1 therapy. J Diabetes Investig, 2016; 7: 915–918.

  4. DeFronzo RA: Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes, 2009; 58: 773–795.

  5. Kendall DM, Cuddihy RM, et al: Clinical application of incretin–based therapy: therapeutic potential, patient selection and clinical use. Am J Med, 2009; 122: S37–S50.

  6. Weyer C, Bogardus C, et al: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest, 1999; 104: 787–794.

  7. Suzuki K, Akiyama M, et al: Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population. Nat Genet, 2019; 51: 379–386.

  8. Kume S, Kondo M, et al: Hypothalamic AMP–activated protein kinase regulates biphasic insulin secretion from pancreatic β cells during fasting and in type 2 diabetes. EBioMedicine, 2016; 13: 168–180.